Michel Afargan

Dr. Afargan has over 25 years of experience as a Senior Executive in Drug Discovery and Development. He served as CTO, CEO, and Chairman of several Biomed startups and public companies. Dr. Afargan is co-author of 7 INDs, 2 IDEs, and 2 505(B)2. Since 2012, Dr. Afargan has been the leading Lecturer of Pharmaceutical Sciences, School of Pharmacy, Hebrew University, Jerusalem, Israel. He is the innovator of the novel peptide-based drug Somatoprim® for the treatment of metabolic disorders and adenocarcinomas, and inventor of a series of issued and pending patents in innovative drug delivery systems, diagnostics, and new drug entities of small molecules and peptide-based drugs.

Dr. Afargan received a B.Sc. in Life Sciences, M.Sc. (S) in Molecular Biology, License in Pharmacy (B. Pharm.), M.Sc. Pharmaceutical Sciences and Ph.D. in Pharmaceutical and Life Sciences (Hebrew University, Israel).